White House sides with GSK sales reps

Share this article:
Glaxo signage touts firm's drug-testing role in '12 Games
Glaxo signage touts firm's drug-testing role in '12 Games
The U.S. Solicitor General has filed an amicus brief siding with two pharmaceutical sales reps in their overtime case against GlaxoSmithKline.

The lawsuit alleges that the company denied the reps overtime pay by improperly considering them outside salesmen. The term is defined by the Department of Labor, which also has definitions which distinguish between sales and promotional work.

The Solicitor General's brief argues that the plaintiffs fall in the promotional category, because unlike salesmen, they cannot take orders, negotiate prices or determine a patient's best interest – the latter being a physician's job.

The brief concedes that drug reps could be considered salesmen, if only in a colloquial sense, “because they seek to persuade physicians.”

GSK has argued that the sales reps trigger sales, but the Solicitor General's brief says that restrictions surrounding a drug rep's practice make it “impossible to determine with certainty whether a PSR's promotional work induced any particular prescription.”

Novartis settled a similar suit in January, for $99 million, and Schering-Plough was found to owe overtime pay in August.

The Supreme Court is set to hear the sales rep/GSK appeal this spring.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.